SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Q3 FY 24 conference call15-02-2024
15-02-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q3 Conference call15-02-2024
SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot Notice for Approval for Issue of Securities of the Company by way of Qualified Institutions Placement (QIP)12-02-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Quarter & Nine months ended 31 December 202408-02-2024
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Board Meeting Outcome
Board Meeting Outcome08-02-2024
SHILPA MEDICARE LTD. - 530549 - Results - Quarter Ended 31 December 2023
Un-Audited standalone & consolidated financial results for the quarter and nine months ended 31 December 202308-02-2024
SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Declaration of Postal Ballot Results & Scrutinizers Report with respect to Reclassification from promoter group to public06-02-2024
SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 SEBI (LODR) Reg 2015
Europe (EMA) Inspection of Bio- Analytical Laboratory, Unit 7, Shilpa Medicare Limited, Nacharam, Hyderabad, Telengana06-02-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 & Nine Months FY24 Conference Call to be held on Monday, 12th February 2024 at 11:30 AM IST.06-02-2024
SHILPA MEDICARE LTD. - 530549 - Update on board meeting
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve To consider and approve raising of funds through issuance of eligible securities of the company by way of one or more public and/or private offerings including on a preferential allotment basis and/or a qualified institutions placement and/or rights issue and/or further public offering05-02-2024